AGIO — Agios Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $2.66bn
- $2.09bn
- $26.82m
R2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 14.2 | 26.8 |
Cost of Revenue | |||||
Gross Profit | — | — | — | 12.5 | 23.9 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 316 | 336 | 372 | 266 | 418 |
Operating Profit | -316 | -336 | -372 | -251 | -391 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -301 | -329 | -357 | -232 | -352 |
Net Income After Taxes | -301 | -329 | -357 | -232 | -352 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -411 | -327 | 1,605 | -232 | -352 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -411 | -327 | 1,605 | -232 | -352 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -5.02 | -4.77 | -6.01 | -6.74 | -6.33 |